Payment overview · 2025
General Payments
$337.30
15 reported records · 8 companies
Healthcare provider profile · identity verified
Amber Davis, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LUFKIN, TX · NPI 1659904712
Verified facts
What the public records show
CMS Open Payments records show Amber Davis, APRN received $337.30 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.96 | 20.4% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $64.41 | 19.1% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $63.02 | 18.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $51.73 | 15.3% | 2 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $28.71 | 8.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.07 | 6.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.07 | 6.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.33 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $337.30 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $79.84 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $63.02 | 3 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $36.30 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 217 | 70 |
| Lisinopril | Lisinopril | 151 | 47 |
| Gabapentin | Gabapentin | 142 | 40 |
| Losartan Potassium | Losartan Potassium | 117 | 35 |
| Ozempic | Semaglutide | 114 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 24 |
| Alendronate Sodium | Alendronate Sodium | 75 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 19 |
| Trazodone Hcl | Trazodone Hcl | 64 | 16 |
| Furosemide | Furosemide | 62 | 15 |
| Allopurinol | Allopurinol | 52 | 13 |
| Omeprazole | Omeprazole | 52 | 18 |
| Metformin Hcl Er | Metformin Hcl | 50 | 14 |
| Montelukast Sodium | Montelukast Sodium | 50 | 16 |
| Metformin Hcl | Metformin Hcl | 47 | 17 |
| Ezetimibe | Ezetimibe | 46 | 17 |
| Simvastatin | Simvastatin | 44 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 12 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 13 |
| Sertraline Hcl | Sertraline Hcl | 40 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 15 |
| Glipizide Er | Glipizide | 38 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $337.30 · 15 records | ABBVIE INC. | AYVAKIT, Bimzelx, DUPIXENT, ELIQUIS, NEXLETOL, NURTEC ODT, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, TREMFYA, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error